Optimal timing for antihypertensive dosing: Focus on valsartan

Therapeutics and Clinical Risk Management

Volumn 3, Issue 1, 2007, Pages 119-131

  Hermida, Ramón C ^a   Ayala, Diana E ^a   Calvo, Carlos ^b  

^a UNIVERSITY OF VIGO   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

Ambulatory blood pressure monitoring; Chronotherapy; Circadian rhythm; Dipper; Hypertension; Nondipper; Valsartan

Indexed keywords

ALBUMIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FIBRINOGEN; IMIDAPRIL; ISRADIPINE; NEBIVOLOL; NIFEDIPINE; NISOLDIPINE; NITRENDIPINE; PERINDOPRIL; PLACEBO; PROPRANOLOL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; MONOTHERAPY; PERIPHERAL EDEMA; PROTEIN URINE LEVEL; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

EID: 34247584529     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2007.3.1.119     Document Type: Review

References (83)

1. Anwar YA, Giacco S, McCabe EJ, et al. 1998. Evaluation of the efficacy of the Omron HEM-737 Intellisense device for use on adults according to the recommendations of the Association for the Advancement of Medical Instrumentation. Blood Press Monit, 3:261-5.
2. Baumgart P. 1991. Circadian rhythm of blood pressure: Internal and external triggers. Chronobiol Int, 8:444-50.
3. Bianchi S, Bigazzi R, Baldari G, et al. 1994. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens, 7:23-9.
4. Chobanian AV, Bakris GL, Black HR, et al. 2003. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA, 289:2560-71.
5. Davis BR, Cutler JA, Furberg CD, et al. 2002. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: Further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Ann Intern Med, 137(5 part 1):313-20.
6. de Leeuw PW, Falke HE, Kho TL, et al. 1977. Effects of beta-agrenergic blockade on diurnal variability of blood pressure and plasma noradrenaline levels. Acta Med Scand, 202:3 89-92.
7. Ebata H, Hojo Y, Ikeda U, et al. 1995. Differential effects of an alpha 1-blocker (doxazosin) on diurnal blood pressure variation in dipper and non-dipper type hypertension. Hypertens Res, 18:125-30.
8. Eguchi K, Kario K, Shimada K. 2002. Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hypertens Res, 25:329-33.
9. Fernández JR, Hermida RC. 1998. Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations. Chronobiol Int, 15:191-204.
10. Fernández JR, Mojón A, Hermida RC. 2004. Comparison of parameters from rhythmometric models with multiple components on hybrid data. Chronobiol Int, 21:469-84.
11. Fogari R, Malacco E, Tettamanti F, et al. 1993. Evening vs. morning isradipine sustained release in essential hypertension: a double-blind study with 24 h ambulatory monitoring. Br J Clin Pharmacol, 35:51-4.
12. Greminger P, Suter PM, Holm D, et al. 1994. Morning versus evening administration of nifedipine gastrointestinal therapeutic system in the management of essential hypertension. Clin Invest, 72:864-9.
13. Guidelines Committee. 2003. European Society of Hypertension - European Society of Cardiology guiudelines for the management of arterial hypertension. J Hypertens, 21:1011-53.
14. Hermida RC, Smolensky MH. 2004. Chronotherapy of hypertension. Curr Opin Nephrol Hypertens, 13:501-5.
15. Hermida RC, Ayala DE, Fernández JR, et al. 2002. Modeling the circadian variability of ambulatorily monitored blood pressure by multiple-component analysis. Chronobiol Int, 19:461-81.
16. Hermida RC, Ayala DE. 2003. Sampling requirements for ambulatory blood pressure monitoring in the diagnosis of hypertension in pregnancy. Hypertension, 42:619-24.
17. Hermida RC, Calvo C, Ayala DE, et al. 2002a. Relationship between physical activity and blood pressure in dipper and nondipper hypertensive patients. J Hypertens, 20:1097-104.
18. Hermida RC, Calvo C, Ayala DE, et al. 2002b. Evaluation of the extent and duration of the "ABPM effect" in hypertensive patients. J Am Coll Cardiol, 40:710-17.
19. Hermida RC, Calve, C, Ayala DE, et al. 2003a. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects. Hypertension, 42:283-90.
20. Hermida RC, Calvo C, Ayala DE, et al. 2003b. Seasonal variation of fibrinogen in dipper and nondipper hypertensive patients. Circulation, 108:1101-6.
21. Hermida RC, Calvo C, Ayala DE, et al. 2004. Administration-time-dependent effects of doxazosin GITS on ambulatory blood pressure of hypertensive subjects. Chronobiol Int, 21:277-96.
22. Hermida RC, Calvo C, Ayala DE, et al. 2005a. Administration time-dependent effects of Difedipine GITS on ambulatory blood pressure in patients with essential hypertension. Am J Hypertens, 18(5 part 2):63A.
23. Hermida RC, Calvo C, Ayala DE, et al. 2005b. Administration time-dependent effects of nebivolol on ambulatory blood pressure in patients with essential hypertension. Am J Hypertens, 18(5 part 2):63A.
24. Hermida RC, Calvo C, Ayala DE, et al. 2005c. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects. Chronobiol Int, 22:755-76.
25. Hermida RC, Calvo C, Ayala DE, et al. 2005d. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens, 23:1913-22.
26. Hermida RC, Calvo C, Ayala DE, et al. 2005e. Decrease in urinary albumin excretion associated to the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension, 46:960-8.
27. Hermida RC, Calvo C, Ayala DE, et al. 2006. Prediction of cardiovascular events by ambulatory blood pressure and effects of Chronotheraoy: The MAPEC study. J Hypertens, 24(suppl 4): S180.
28. Holm S. 1979. A simple sequentially rejective multiple test procedure. Scand J Stat, 6:65-70.
29. Ingelsson E, Bjorklund-Bodegard K, Lind L, et al. 2006. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA, 295:2859-66.
30. Kamoi K, Ikarashi T. 2005. The bedtime administration of doxazosin controls morning hypertension and albuminuria in patients with type-2 diabetes: Evaluation using home-based blood pressure measurements. Clin Exp Hypertens, 4:369-76.
31. Kario K, Schwartz JE, Pickering TG. 2000. Changes of nortunal blood pressure dipping status in hypertensives by nighttime dosing of a-adrenergic blocker, doxazosin. Results from the HALT study. Hypertension, 35:787-94.
32. Kario K, Shimada K. 1997. Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure. Am J Hypertens, 10:261-8.
33. Kikuya M, Ohkubo T, Asayama K, et al. 2005. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension, 45:240-5.
34. Kitahara Y, Saito F, Akao M, ct al. 2004. Effect of morning and bedtime dosing with cilnidipine on blood pressure, heart rate, and sympathetic nervous activity in essential hypertensive patients. J Cardiovasc Pharmacol, 43:68-73.
35. Kohno I, Ijiri H, Takusagawa M, et al. 1999. Chronotherapy of dipper and non-dipper type hypertension with bunazisin-retard: Morning versus evening administration. Am J Hypertens, 12(4 Part 2):156A.
36. Kohno I, Ijiri H, Takusagawa M, et al. 2000. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int, 17:209-19.
37. Kohno I, Iwasaki H, Okutani M, et al. 1997. Administration-time-dependent effects of diltiazem on the 24-hour blood pressure profile of essential hypertension patients. Chronobiol Int, 14:71-84.
38. Kuroda T, Kario K, Hoshide S, et al. 2004. Effects of bedtime vs. morning administration of the long-acting lipophilic angiotensin-converting enzyme inhibitor trandolapril on morning blood pressure in hypertensive patients. Hypertens Res, 27:15-20.
39. Labrecque G, Beauchamp D. 2003. Rhythms and pharmacokinetics. In: Redfern P (ed). Chronotherapeutics. London, England: Pharmaceutical Pr, pp 75-110.
40. Langner B, Lemmer B. 1988. Circadian changes in the pharmacokinetics and cardiovascular effects of oral propranolol in healthy subjects. Eur J Clin Pharmacol, 33:619-24.
41. Lemmer B, Nold G, Behne S, et al. 1991. Chronopharmacokinctics and cardiovascular effects of nifedipine. Chronobiol Int, 8:485-94.
42. Lemmer B, Portaluppi F. 1997. Chronopharmacology of cardiovascular diseases. In: Redfern P, Lemmer B (eds). Handbook of Experimental Pharmacology, Vol 125, Physiology and Pharmacology of Biological Rhythms. Heidelberg, Germany: Springer Verlag, pp 251-97.
43. Lemmer B. 1992. Cardiovascular chronobiology and chronopharmacology. In: Touitou Y, Hans E, (eds). Biologic Rhythms in Clinical and Laboratory Medicine. Berlin, Germany: Springer-Verlag, pp 418-27.
44. Lemmer B. 2000. Cardiovascular chronobiology and chronopharmacology. Importance of timing of dosing. In: White WB (ed). Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Pr, pp 255-271.
45. Mansoor GA, White WB, McCabe EJ, et al. 2000. The relationship of electronically monitored physical activity to blood pressure, heart rate, and the circadian blood pressure profile. Am J Hypertens, 13:262-7.
46. Meilhac B, Mallion JM, Carte A, et al. 1992. Study of the influence of the time of administration on the antihypertensive effect and nitrendipine tolerance in mild to moderate essential hypertensive patients. Value of ambulatory recording of blood pressure on 24 hours. Therapie, 47:205-10.
47. Mengden T, Binswanger B, Gruene S. 1992. Dynamics of drug compliance and 24-hour blood pressure control of once daily morning vs evening amlodipine. J Hypertens, 10(SuppI 4): S136.
48. Mochizuki Y, Okutani M, Donfeng Y, et al. 1998. Limited reproducibility of circadian variation in blood pressure dippers and nondippers. Am J Hypertens, 11:403-9.
49. Morgan T, Anderson A, Jones E. 1997. The effect on 24 h blood pressure control of an angiotensin converting enzyme inhibitor (perindopril) administered in the morning or at night. J Hypertens, 15:205-11.
50. Myburgh DP, Verho M, Botes JH, et al. 1995. 24-Hour pressure control with ramipril: comparison of once-daily morning and evening administration. Curr Ther Res, 56:1298-306.
51. Nold G, Strobel G, Lemmer B. 1998. Morning vs evening amlodipine treatment: effect on circadian blood pressure profile in essential hypertensive patients. Blood Press Monit, 3:17-25.
52. Nozawa M, Sugimoto K, Ohmori M, et al. 2006. Dosing time-dependent effect of temocapril on the mortality of stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther, 316:176-81.
53. O'Brien A, Asmar R, Beilin L, et al. 2003. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens, 21:821-48.
54. O'Brien E, Sheridan J, O'Malley K. 1988. Dippers and non-dippers. Lancet, 13:397.
55. O'Brien E, Staessen J. 1995. Normotension and hypertension as defined by 24-hour ambulatory blood pressure monitoring. Blood Press, 4:266-82.
56. Obkubo T, Hozawa A, Yamaguchi J, et al. 2002. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study. J Hypertens, 20:2183-9.
57. Palatini P, Mos L, Motolese M, et al. 1993. Effect of evening versus morning benazepril on 24-hour blood pressure: a comparative study with continuous intraarterial monitoring. Int J Clin Pharmacol Ther Toxicol, 31:295-300.
58. Palatini P, Racioppa A, Raule G, et al. 1992. Effect of timing of administration on the plasma ACE inhibitory activity and the antihypertensive effect of quinapril. Clin Pharmacol Ther, 52:378-83.
59. Palatini P. 1992. Can an angiotensin-converting enzyme inhibitor with a short half-life effectively lower blood pressure for 24 hours? Am Heart J, 123:1421-5.
60. Panza JA, Epstein SE, Quyyumi AA. 1991. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med, 325:986-90.
61. Pickering TG, Hall JE, Appel LJ, et al. 2005. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurement in humans. Hypertension, 45:142-61.
62. Pickering TG, Levenstein M, Walmsley P; for the Hypertension and Lipid Trial Study Group. 1994. Night-time dosing of doxazosin has peak effect on morning ambulatory blood pressure. Results of the HALT study. Am J Hypertens, 7:844-7.
63. Portaluppi F, Smolensky MH. 2000. Circadian rhythm and environmental determinants of blood pressure regulation in normal and hypertensive conditions. In: White WB (ed). Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totowa, NJ: Humana Pr, pp 79-118.
64. Portaluppi F, Vergnani L, Manfredini R, et al. 1995. Time-dependent effect of isradipme on the nocturnal hypertension in chronic renal failure. Am J Hypertens, 8:719-26.
65. Qiu YG, Chen JZ, Zhu JH, et al. 2003. Differential effects of morning or evening dosing of amlodipine on circadian blood pressure and heart rate. Cardiovasc Drugs Ther, 17:335-41.
66. Ruggenenti P, Schieppati A, Remuzzi G. 2001. Progression, remission, regression of chronic renal disease. Lancet, 357:1601-8.
67. Sica DA, Wilson DK. 2000. Sodium, potassium, the sympathetic nervous system, and the renin-angiotensin system: Impact on the circadian variability in blood pressure. In: White WB (ed). Blood Pressure Monitoring in Cardiovascular Medicine and Therapeutics. Totoya, NJ: Humana Pr, pp 171-90.
68. Smith DH, Neutel JM, Lacourciere Y, et al. 2003. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J Hypertens, 21:1291-8.
69. Smolensky MH, Haus E. 2001. Circadian rhythms in clinical medicine with applications to hypertension. Am J Hypertens, 14:280S-90S.
70. Smolensky MH. 1997. Chronobiology and chronotherapeutics: Applications to cardiovascular medicine. In: Deedwania PC (ed). Circadian Rhythms of Cardiovascular Disorders. Armonk, N.Y.: Futura Publishing Co., Inc, pp 173-206.
71. Staessen J, Fagard R, Lijnen P, et al. 1991. Ambulatory blood pressure monitoring in clinical trials. J Hypertens, 9(SuppI 1):s13-19.
72. Staessen JA, Thijs L, Fagard R, et al. 1999. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. JAMA, 282:539-546.
73. Stanton A, O'Brien E. 1994. Auswitkungen der Therapie auf das zirkadianc. Blutdruckprofil Kar-dio, 3:1-8.
74. Svensson P, de Faire U, Sleight P, et al. 2001. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension, 38:e28-32.
75. The ALLHAT Collaborative Research Group. 2000. Major cardiovascular events in Hypertensive patients randomized to doxazosin vs. chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA, 283:1967-75.
76. Timio M, Lolli S, Verdura C, et al. 1993. Circadian blood pressure changes in patients with chronic renal insufficiency: a prospective study. Ren Fail, 15:231-7.
77. Umeda T, Naomi S, Iwaoka T, et al. 1994. Timing for administration of an antiltypertensive drug in the treatment of essential hypertension. Hypertension, 23(Suppl 1):1211-14.
78. Verdecchia P, Porcellati C, Schillaci G, et al. 1994. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension, 24:793-801.
79. White WB, Mansoor GA, Pickering TG, et al. 1999. Differential effects of morning and evening dosing of nisoldipine ER on circadian blood pressure and heart rate. Am J Hypertens, 12:806-14.
80. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, et al. 1984. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med, 311:501-5.
81. Witte K, Lemmer B. 2003. Rhythms and pharmacodynamics. In: Redfern P (ed). Chronotherapeutics. London, England: Pharmaceutical Pr, pp 111-26.
82. Witte K, Weisser K, Neubeck M, et al. 1993. Cardiovascular effects, pharmacokinetics and converting enzyme inhibition of enalapril after morning versus evening administration. Clin Pharmacol Ther, 54:177-86.
83. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.